PubRank

An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification

Clinical Trial ID NCT01953926

PubWeight™ 15.46‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01953926

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. Clin Cancer Res 2015 2.12
2 Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol 2016 1.18
3 HER2 activating mutations are targets for colorectal cancer treatment. Cancer Discov 2015 1.07
4 Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges. Neuro Oncol 2014 1.05
5 Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies. Oncologist 2015 0.92
6 Profile of neratinib and its potential in the treatment of breast cancer. Breast Cancer (Dove Med Press) 2015 0.86
7 Modelling bladder cancer in mice: opportunities and challenges. Nat Rev Cancer 2015 0.86
8 Precision medicine for metastatic breast cancer-limitations and solutions. Nat Rev Clin Oncol 2015 0.85
9 Evaluation of targeted therapies in advanced breast cancer: the need for large-scale molecular screening and transformative clinical trial designs. Oncogene 2015 0.82
10 Genetic profiles of cervical tumors by high-throughput sequencing for personalized medical care. Cancer Med 2015 0.81
11 HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor. J Natl Compr Canc Netw 2015 0.79
12 Novel molecular targets for urothelial carcinoma. Expert Opin Ther Targets 2015 0.76
13 ERBB2 emerges as a new target for colorectal cancer. Cancer Discov 2015 0.76
14 Successful treatment of a patient with Li-Fraumeni syndrome and metastatic lung adenocarcinoma harboring synchronous EGFR L858R and ERBB2 extracellular domain S310F mutations with the pan-HER inhibitor afatinib. Cancer Biol Ther 2014 0.75
15 Genomic diversity of colorectal cancer: Changing landscape and emerging targets. World J Gastroenterol 2016 0.75
16 New generation of breast cancer clinical trials implementing molecular profiling. Cancer Biol Med 2016 0.75
17 Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness. Ther Adv Med Oncol 2016 0.75
Next 100